Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

por Gagez, A-L, Tuaillon, E, Cezar, R, Dartigeas, C, Mahé, B, Letestu, R, Maisonneuve, H, Gouilleux-Gruart, V, Bollore, K, Ferrant, E, Aurran, T, Feugier, P, Leprêtre, S, Cartron, G
Publicado 2016

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

por Vincent, L, Ceballos, P, Plassot, C, Méniane, J C, Quittet, P, Navarro, R, Cyteval, C, Szablewski, V, Lu, Z Y, Kanouni, T, Moreaux, J, Cartron, G, Klein, B, Fegueux, N
Publicado 2015

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE II...

por Cartron, G., Bachy, E., Tilly, H., Daguindau, N., Pica, G.-M., Bijou, F., Mounier, C., Clavert, A. M., Damaj, G. L., Slama, B., Casasnovas, O., Houot, R., Bouabdallah, K., Sibon, D., Fitoussi, O., Morineau, N., Herbaux, C., Gastinne, T., Fornecker, L.-M., Haioun, C., Launay, V., Araujo, C., Benbrahim, O., Sanhes, L., Gressin, R., Gonzalez, H., Morschhauser, F., Xerri, L., Tarte, K., Pranger, D.
Publicado 2022